Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) have earned a consensus rating of “Moderate Buy” from the nine analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $31.3333.

A number of research analysts have recently commented on GLUE shares. Wells Fargo & Company upped their price target on Monte Rosa Therapeutics from $22.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, January 8th. Wedbush reaffirmed an “outperform” rating and set a $37.00 price objective on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Weiss Ratings reiterated a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research note on Monday, December 29th. TD Cowen reissued a “buy” rating on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th. Finally, Jefferies Financial Group restated a “buy” rating and set a $31.00 price target on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 7th.

Monte Rosa Therapeutics Stock Down 4.1%

Monte Rosa Therapeutics stock opened at $17.75 on Monday. Monte Rosa Therapeutics has a twelve month low of $3.50 and a twelve month high of $25.77. The firm has a 50 day moving average price of $19.88 and a 200-day moving average price of $13.68. The company has a market capitalization of $1.16 billion, a P/E ratio of 55.47 and a beta of 1.63.

Insider Activity

In other news, CEO Markus Warmuth sold 5,466 shares of the firm’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $23.49, for a total value of $128,396.34. Following the completion of the transaction, the chief executive officer directly owned 618,937 shares of the company’s stock, valued at $14,538,830.13. This trade represents a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Monte Rosa Therapeutics

A number of institutional investors have recently added to or reduced their stakes in GLUE. GAMMA Investing LLC purchased a new position in Monte Rosa Therapeutics during the 4th quarter valued at about $30,000. Russell Investments Group Ltd. purchased a new position in Monte Rosa Therapeutics during the third quarter valued at approximately $32,000. Brighton Jones LLC purchased a new position in Monte Rosa Therapeutics during the second quarter valued at approximately $48,000. Lazard Asset Management LLC increased its holdings in Monte Rosa Therapeutics by 42.9% during the 2nd quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after acquiring an additional 3,262 shares during the period. Finally, Nisa Investment Advisors LLC lifted its stake in Monte Rosa Therapeutics by 16.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after purchasing an additional 451 shares in the last quarter. Hedge funds and other institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.